Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Blueprint Medicines (BPMC) Tops Q4 EPS by 9c
February 17, 2021 7:14 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.53), $0.09 better than the analyst estimate of ($1.62). Revenue for the quarter came in at $34.1 million versus the consensus estimate of $29.24 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More